Fox Chase’s Dr. Elizabeth Plimack Appointed Treasurer of American Society of Clinical Oncology

Dr plimack
Elizabeth Plimack, MD, MS, has been appointed Treasurer of the American Society of Clinical Oncology.

PHILADELPHIA (June 2, 2023)—Elizabeth Plimack, MD, MS, Deputy Director and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Treasurer of the American Society of Clinical Oncology (ASCO).

“ASCO is an exemplary organization, bound closely by its mission, with a track record of successful, innovative programs. Strategic investment in these important initiatives requires sound financial stewardship, and I am honored to have been nominated by the board to the position of Treasurer and look forward to supporting the efforts of Linda Jensen, Vice President and Chief Financial Officer of ASCO, over the coming year,” said Plimack.

In 2019, Plimack was elected to a four-year term on ASCO’s Board of Directors. A professional medical society of nearly 45,000 members, ASCO works to conquer cancer through research, education, and promotion of the highest quality patient care.

A national leader in genitourinary oncology, Plimack joined Fox Chase in 2008 after completing her medical oncology fellowship at the MD Anderson Cancer Center in Houston.

Internationally recognized for her expertise in bladder and kidney cancers, Plimack is a leader in clinical trial design and implementation. Her research has formed the basis of a biomarker-directed bladder preservation platform led by Fox Chase investigators.

She leads a multicenter clinical trial in metastatic bladder cancer funded by Stand Up To Cancer. She has also been active in drug development on steering committees and data safety boards of trials that have led to the approval of multiple new agents used to treat patients with genitourinary malignancies.

Plimack earned her medical degree with honors in Pathology from the New York University School of Medicine and a Master of Science in Patient-Based Biologic Research from the University of Texas Graduate School of Biomedical Sciences. She completed both her internship and internal medicine residency at New York University Medical Center/Bellevue Hospital.

Among her many professional activities and leadership roles, Plimack is chair of the Scientific Advisory Board for the Bladder Cancer Advocacy Network and a member of the National Comprehensive Cancer Network (NCCN) Board of Directors.

In addition, she is a member of the NCCN guidelines panels for bladder/penile cancers. She is the medical oncology editor of European Urology—the official journal of the European Association of Urology—and also serves on the editorial boards of Cancer and the Journal of Clinical Oncology.

Consistently named a Philadelphia magazine Top Doctor, Plimack also appears regularly in Castle Connolly’s Top Doctors. She has also achieved status as a five-star provider, the highest possible rating for clinical care based on patient satisfaction data compiled by Press Ganey, a company focused on improving healthcare.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427